Compare Stocks: REPL, XENE, CRSP, and LGND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$57.72 -2.8%	$53.62	$44.12 ▼ $78.48	$5.58B	1.74	1.50 million shs	1.39 million shs
LGND Ligand Pharmaceuticals	$280.49 -1.4%	$297.75	$160.05 ▼ $326.63	$5.59B	1.13	235,814 shs	127,695 shs
REPL Replimune Group	$15.50 -0.6%	$11.84	$1.50 ▼ $16.15	$1.45B	0.88	6.20 million shs	2.39 million shs
XENE Xenon Pharmaceuticals	$59.99 -3.1%	$63.18	$35.60 ▼ $72.66	$5.80B	0.62	678,788 shs	587,903 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-2.99%	+19.16%	+2.90%	+7.83%
LGND Ligand Pharmaceuticals	0.00%	-2.03%	-5.33%	+20.92%	+76.30%
REPL Replimune Group	0.00%	+4.94%	+181.82%	+78.37%	+180.29%
XENE Xenon Pharmaceuticals	0.00%	-1.28%	-6.54%	+9.61%	+54.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$57.72 -2.8%	$53.62	$44.12 ▼ $78.48	$5.58B	1.74	1.50 million shs	1.39 million shs
LGND Ligand Pharmaceuticals	$280.49 -1.4%	$297.75	$160.05 ▼ $326.63	$5.59B	1.13	235,814 shs	127,695 shs
REPL Replimune Group	$15.50 -0.6%	$11.84	$1.50 ▼ $16.15	$1.45B	0.88	6.20 million shs	2.39 million shs
XENE Xenon Pharmaceuticals	$59.99 -3.1%	$63.18	$35.60 ▼ $72.66	$5.80B	0.62	678,788 shs	587,903 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	-2.99%	+19.16%	+2.90%	+7.83%
LGND Ligand Pharmaceuticals	0.00%	-2.03%	-5.33%	+20.92%	+76.30%
REPL Replimune Group	0.00%	+4.94%	+181.82%	+78.37%	+180.29%
XENE Xenon Pharmaceuticals	0.00%	-1.28%	-6.54%	+9.61%	+54.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.61	Moderate Buy	$68.06	17.91% Upside
LGND Ligand Pharmaceuticals	3.00	Buy	$335.75	19.70% Upside
REPL Replimune Group	2.60	Moderate Buy	$12.00	-22.58% Downside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	28.58% Upside

Current Analyst Ratings Breakdown

Latest REPL, XENE, CRSP, and LGND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2026	REPL Replimune Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$20.00 ➝ $21.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/14/2026	LGND Ligand Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$330.00
8/12/2026	REPL Replimune Group	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/11/2026	LGND Ligand Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Buy (B-)
8/11/2026	REPL Replimune Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/7/2026	REPL Replimune Group	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$12.00
8/7/2026	LGND Ligand Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$340.00 ➝ $345.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$11M	507.37	N/A	N/A	$18.06 per share	3.20
LGND Ligand Pharmaceuticals	$268.09M	20.86	$7.85 per share	35.72	$48.53 per share	5.78
REPL Replimune Group	N/A	N/A	N/A	N/A	$1.13 per share	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	$12.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
LGND Ligand Pharmaceuticals	$124.45M	$9.35	30.00	33.12	2.25	67.88%	20.06%	11.68%	11/5/2026 (Estimated)
REPL Replimune Group	-$313.94M	-$3.15	N/A	N/A	N/A	N/A	-159.32%	-90.84%	11/5/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest REPL, XENE, CRSP, and LGND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q1 2027	REPL Replimune Group	-$0.6940	-$0.72	-$0.0260	-$0.72	$13.60 million	N/A
8/6/2026	Q2 2026	LGND Ligand Pharmaceuticals	$1.97	$2.37	+$0.40	$2.22	$61.30 million	$63.69 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million
6/29/2026	Q4 2026	REPL Replimune Group	-$0.6613	-$0.76	-$0.0988	-$0.76	$3.57 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
LGND Ligand Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
REPL Replimune Group	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	0.34	17.85	17.85
LGND Ligand Pharmaceuticals	1.16	31.18	30.96
REPL Replimune Group	1.00	5.23	5.23
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
LGND Ligand Pharmaceuticals	91.28%
REPL Replimune Group	92.53%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	5.20%
LGND Ligand Pharmaceuticals	5.60%
REPL Replimune Group	5.40%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
LGND Ligand Pharmaceuticals	80	19.94 million	18.82 million	Optionable
REPL Replimune Group	210	93.80 million	88.73 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

REPL, XENE, CRSP, and LGND Headlines

Recent News About These Companies

Hsbc Holdings PLC Invests $9.14 Million in Xenon Pharmaceuticals Inc. $XENE

August 29 at 5:37 AM | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28 at 4:11 PM | financialpost.comF

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28 at 4:01 PM | globenewswire.com

What Xenon Pharmaceuticals (XENE)'s New Azetukalner Phase 3 Epilepsy Data Means For Shareholders

August 28 at 7:46 AM | finance.yahoo.com

51,345 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Palo Alto Investors LP

August 28 at 6:31 AM | marketbeat.com

Man Group plc Acquires New Stake in Xenon Pharmaceuticals Inc. $XENE

August 28 at 5:28 AM | marketbeat.com

Cibc World Market Inc. Takes $1.21 Million Position in Xenon Pharmaceuticals Inc. $XENE

August 28 at 3:52 AM | marketbeat.com

Bamco Inc. NY Buys Shares of 25,000 Xenon Pharmaceuticals Inc. $XENE

August 28 at 3:05 AM | marketbeat.com

33,300 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Seven Fleet Capital Management LP

August 27 at 6:24 AM | marketbeat.com

Jupiter Topco LLC Acquires New Holdings in Xenon Pharmaceuticals Inc. $XENE

August 27 at 5:28 AM | marketbeat.com

65,000 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Artia Global Partners LP

August 27 at 3:04 AM | marketbeat.com

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

August 26, 2026 | financialpost.comF

Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026

August 26, 2026 | globenewswire.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 5% - Should You Buy?

August 26, 2026 | marketbeat.com

Trails Edge Capital Partners LP Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

August 26, 2026 | marketbeat.com

Castleark Management LLC Takes Position in Xenon Pharmaceuticals Inc. $XENE

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Xenon Pharmaceuticals Inc. $XENE

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Invests $23.99 Million in Xenon Pharmaceuticals Inc. $XENE

August 25, 2026 | marketbeat.com

Nicholas Investment Partners LP Purchases New Position in Xenon Pharmaceuticals Inc. $XENE

August 25, 2026 | marketbeat.com

BlackRock Inc. Invests $454.06 Million in Xenon Pharmaceuticals Inc. $XENE

August 25, 2026 | marketbeat.com

Algert Global LLC Grows Stock Position in Xenon Pharmaceuticals Inc. $XENE

August 25, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, XENE, CRSP, and LGND Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$57.72 -1.65 (-2.78%)

As of 08/28/2026 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ligand Pharmaceuticals NASDAQ:LGND

$280.49 -4.03 (-1.42%)

As of 08/28/2026 04:00 PM Eastern

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Replimune Group NASDAQ:REPL

$15.50 -0.10 (-0.64%)

As of 08/28/2026 04:00 PM Eastern

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$59.99 -1.94 (-3.13%)

As of 08/28/2026 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, XENE, CRSP, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, XENE, CRSP, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, XENE, CRSP, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, XENE, CRSP, and LGND Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Ligand Pharmaceuticals NASDAQ:LGND

Replimune Group NASDAQ:REPL

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest REPL, XENE, CRSP, and LGND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest REPL, XENE, CRSP, and LGND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

REPL, XENE, CRSP, and LGND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL, XENE, CRSP, and LGND Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

Ligand Pharmaceuticals NASDAQ:LGND

Replimune Group NASDAQ:REPL

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools